The technique of autologous HSCT is very well established and has been performed since the 1970s. The risk of autologous HSCT is relatively low because it is supported by high-dose chemotherapy with one’s own HSC. Complications associated with transplantation are common, such as infection, bleeding and other complications that are less likely to occur, such as problems with the quantity or quality of stem cells collected. There are also problems with hematopoietic reconstitution and failure to reconstitute the hematopoietic cells as in the case of reblast, which is also a risk of autologous HSCT. There are other very rare and serious complications, but the overall safety is relatively high and the incidence of serious adverse reactions is relatively low.